REFERENCES
1. Gordon LB, Massaro J, D’Agostino RB Sr, et al. Impact of farnesylation inhibitors on survival in Hutchinson-Gilford progeria syndrome. Circulation 2014;130:27-34.
2. Puttaraju M, Jackson M, Klein S, et al. Systematic screening identifies therapeutic antisense oligonucleotides for Hutchinson-Gilford progeria syndrome. Nat Med 2021;27:526-35.
3. Erdos MR, Cabral WA, Tavarez UL, et al. A targeted antisense therapeutic approach for Hutchinson-Gilford progeria syndrome. Nat Med 2021;27:536-45.
4. Beyret E, Liao HK, Yamamoto M, et al. Single-dose CRISPR-Cas9 therapy extends lifespan of mice with Hutchinson-Gilford progeria syndrome. Nat Med 2019;25:419-22.
5. Santiago-Fernández O, Osorio FG, Quesada V, et al. Development of a CRISPR/Cas9-based therapy for Hutchinson-Gilford progeria syndrome. Nat Med 2019;25:423-6.
6. Anzalone AV, Koblan LW, Liu DR. Genome editing with CRISPR-Cas nucleases, base editors, transposases and prime editors. Nat Biotechnol 2020;38:824-44.
7. Koblan LW, Erdos MR, Wilson C, et al. In vivo base editing rescues Hutchinson-Gilford progeria syndrome in mice. Nature 2021;589:608-14.